Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学BCL-2 Inhibition, CLL

John Seymour

MBBS, PhD

🏢Peter MacCallum Cancer Centre🌐Australia

Director, Department of Haematology

85
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

John Seymour led the pivotal MURANO trial establishing venetoclax plus rituximab as a fixed-duration regimen for relapsed chronic lymphocytic leukemia. His work demonstrated durable minimal residual disease negativity and reshaped CLL management away from indefinite therapy. He remains a principal investigator in global trials of BCL-2 and BTK inhibitor combinations.

Share:

🧪Research Fields 研究领域

CLL
venetoclax
MURANO trial
lymphoma
fixed-duration therapy

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 John Seymour 的研究动态

Follow John Seymour's research updates

留下邮箱,当我们发布与 John Seymour(Peter MacCallum Cancer Centre)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment